Aldagen

Aldagen, a subsidiary of Cytomedix, Inc., specializes in developing regenerative cell therapies targeting vascular conditions. The company utilizes proprietary technology to isolate a specific population of stem cells from a patient's bone marrow, which constitutes less than 1% of all bone marrow cells. These isolated cells have shown potential in preclinical studies and clinical trials to promote the regeneration of various cell types and tissues, including the formation of new blood vessels, known as angiogenesis. Aldagen's product pipeline includes ALD-301 for critical limb ischemia, ALD-201 for ischemic heart failure, and ALD-401 for ischemic stroke. The company operates in the regenerative medicine market, serving patients with severe vascular conditions. Its business model focuses on developing and commercializing these cell-based therapies, generating revenue through product sales and potential partnerships.

Keywords: regenerative cell therapies, vascular conditions, stem cell isolation, bone marrow, angiogenesis, critical limb ischemia, ischemic heart failure, ischemic stroke, clinical trials, Cytomedix.